# Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

> **NCT00567476** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 116 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Inhaled corticosteroids (ICS)
- **DRUG:** Long-acting beta 2-adrenergic agonist (LABA)
- **DRUG:** Short-acting beta 2-adrenergic agonist (SABA)

## Key facts

- **NCT ID:** NCT00567476
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2011-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567476, "Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00567476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*